Mesporin (Ceftriaxone | Water For Injection)

Ceftriaxone inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This compromises cell‑wall integrity, leading to osmotic lysis and a bactericidal effect against a broad spectrum of Gram‑positive and Gram‑negative organisms.

The dosage of Mesporin is individualized by the prescribing clinician based on the type and severity of infection, patient age, weight, renal and hepatic function, and local antimicrobial susceptibility patterns. No fixed regimen is provided here.

Ceftriaxone is classified as pregnancy category unknown. It should be used only when the potential benefit justifies any potential risk to the fetus. Limited data are available for breastfeeding, and a decision should be made after evaluating the infant’s exposure versus maternal need.

To order Mesporin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Compared with earlier‑generation penicillins, ceftriaxone offers a broader spectrum, greater stability against β‑lactamases, and once‑daily dosing for many infections. It is less active against certain resistant Gram‑negative organisms than carbapenems, but provides a convenient alternative for many community and hospital‑acquired infections.

Mesporin must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Prior to use, the vial should be inspected for particulate matter and reconstituted with the appropriate diluent under aseptic conditions.

Mesporin is supplied as a sterile aqueous solution for intravenous injection. It is administered by slow IV infusion or bolus injection as directed by the prescriber, typically through a dedicated line to avoid incompatibility with calcium‑containing solutions.

The most serious adverse events associated with ceftriaxone include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, significant hepatic injury, hemolytic anemia, and seizures, especially in patients with renal impairment.

Ceftriaxone is contraindicated in patients with a known hypersensitivity to ceftriaxone, other cephalosporins, or penicillins. Caution is also advised for neonates (≤28 days) receiving calcium‑containing solutions due to the risk of precipitation, and for patients with severe hepatic or renal dysfunction without appropriate monitoring.